compounded semaglutide lawsuit news today Novo's GLP-1 Patent Suit Against Hims Takes Aim at Compounding FDA Warns on Certain Forms

Given that both SGLT2i and GLP-1 RA demonstrate robust and consistent cardio-renal benefits [14], both agents seem to be an attractive option to fulfil an unmet therapeutic need in type 1 diabetes

Haas sit down with Josh Holyfield fitness coach, educator, and one of the most straightforward voices in the peptide and optimization space

GI Side Effects (Most Common, Similar to Other GLP-1s) These affect the digestive system and are caused by GLP-1 receptor activation slowing gastric emptying

So why does anyone hesitate to switch

Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety

10,33 Similarly, the REWIND trial, in patients with T2D and established CVD or cardiovascular risk factors, reported that dulaglutide significantly reduced the incidence of MACE (primary outcome)